These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 21790122)

  • 1. Discovery and process synthesis of novel 2,7-pyrrolo[2,1-f][1,2,4]triazines.
    Thieu T; Sclafani JA; Levy DV; McLean A; Breslin HJ; Ott GR; Bakale RP; Dorsey BD
    Org Lett; 2011 Aug; 13(16):4204-7. PubMed ID: 21790122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and SAR of new pyrrolo[2,1-f][1,2,4]triazines as potent p38 alpha MAP kinase inhibitors.
    Wrobleski ST; Lin S; Hynes J; Wu H; Pitt S; Shen DR; Zhang R; Gillooly KM; Shuster DJ; McIntyre KW; Doweyko AM; Kish KF; Tredup JA; Duke GJ; Sack JS; McKinnon M; Dodd J; Barrish JC; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2739-44. PubMed ID: 18364256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2,7-Pyrrolo[2,1-f][1,2,4]triazines as JAK2 inhibitors: modification of target structure to minimize reactive metabolite formation.
    Weinberg LR; Albom MS; Angeles TS; Breslin HJ; Gingrich DE; Huang Z; Lisko JG; Mason JL; Milkiewicz KL; Thieu TV; Underiner TL; Wells GJ; Wells-Knecht KJ; Dorsey BD
    Bioorg Med Chem Lett; 2011 Dec; 21(24):7325-30. PubMed ID: 22041060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of the pyrrolo[2,1-f][1,2,4]triazine nucleus as a new kinase inhibitor template.
    Hunt JT; Mitt T; Borzilleri R; Gullo-Brown J; Fargnoli J; Fink B; Han WC; Mortillo S; Vite G; Wautlet B; Wong T; Yu C; Zheng X; Bhide R
    J Med Chem; 2004 Jul; 47(16):4054-9. PubMed ID: 15267243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.
    Cai ZW; Wei D; Borzilleri RM; Qian L; Kamath A; Mortillo S; Wautlet B; Henley BJ; Jeyaseelan R; Tokarski J; Hunt JT; Bhide RS; Fargnoli J; Lombardo LJ
    Bioorg Med Chem Lett; 2008 Feb; 18(4):1354-8. PubMed ID: 18221875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies to mitigate the bioactivation of 2-anilino-7-aryl-pyrrolo[2,1-f][1,2,4]triazines: identification of orally bioavailable, efficacious ALK inhibitors.
    Mesaros EF; Thieu TV; Wells GJ; Zificsak CA; Wagner JC; Breslin HJ; Tripathy R; Diebold JL; McHugh RJ; Wohler AT; Quail MR; Wan W; Lu L; Huang Z; Albom MS; Angeles TS; Wells-Knecht KJ; Aimone LD; Cheng M; Ator MA; Ott GR; Dorsey BD
    J Med Chem; 2012 Jan; 55(1):115-25. PubMed ID: 22141319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and SAR of 4-(3-hydroxyphenylamino)pyrrolo[2,1-f][1,2,4]triazine based VEGFR-2 kinase inhibitors.
    Borzilleri RM; Cai ZW; Ellis C; Fargnoli J; Fura A; Gerhardt T; Goyal B; Hunt JT; Mortillo S; Qian L; Tokarski J; Vyas V; Wautlet B; Zheng X; Bhide RS
    Bioorg Med Chem Lett; 2005 Mar; 15(5):1429-33. PubMed ID: 15713401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of pyrrolo[2,1-f][1,2,4]triazine C6-ketones as potent, orally active p38α MAP kinase inhibitors.
    Dyckman AJ; Li T; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly KM; Shuster DJ; Doweyko AM; Sack JS; Kish K; Kiefer SE; Newitt JA; Zhang H; Marathe PH; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2011 Aug; 21(15):4633-7. PubMed ID: 21705217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyrrolo[1,2-f]triazines as JAK2 inhibitors: achieving potency and selectivity for JAK2 over JAK3.
    Harikrishnan LS; Kamau MG; Wan H; Inghrim JA; Zimmermann K; Sang X; Mastalerz HA; Johnson WL; Zhang G; Lombardo LJ; Poss MA; Trainor GL; Tokarski JS; Lorenzi MV; You D; Gottardis MM; Baldwin KF; Lippy J; Nirschl DS; Qiu R; Miller AV; Khan J; Sack JS; Purandare AV
    Bioorg Med Chem Lett; 2011 Mar; 21(5):1425-8. PubMed ID: 21282055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha mitogen-activated protein kinase inhibitors.
    Hynes J; Dyckman AJ; Lin S; Wrobleski ST; Wu H; Gillooly KM; Kanner SB; Lonial H; Loo D; McIntyre KW; Pitt S; Shen DR; Shuster DJ; Yang X; Zhang R; Behnia K; Zhang H; Marathe PH; Doweyko AM; Tokarski JS; Sack JS; Pokross M; Kiefer SE; Newitt JA; Barrish JC; Dodd J; Schieven GL; Leftheris K
    J Med Chem; 2008 Jan; 51(1):4-16. PubMed ID: 18072718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyrrolo[2,1-f][1,2,4]triazines: From C-nucleosides to kinases and back again, the remarkable journey of a versatile nitrogen heterocycle.
    Ott GR; Favor DA
    Bioorg Med Chem Lett; 2017 Sep; 27(18):4238-4246. PubMed ID: 28801135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and evaluation of pyrrolo[2,1-f][1,2,4]triazine derivatives as novel hedgehog signaling pathway inhibitors.
    Xin M; Zhang L; Tang F; Tu C; Wen J; Zhao X; Liu Z; Cheng L; Shen H
    Bioorg Med Chem; 2014 Feb; 22(4):1429-40. PubMed ID: 24486203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and antiviral activity of novel 4,5-disubstituted 7-(beta-D-ribofuranosyl)pyrrolo[2,3-d][1,2,3]triazines and the novel 3-amino-5-methyl-1-(beta-D-ribofuranosyl)- and 3-amino-5-methyl-1-(2-deoxy-beta-D-ribofuranosyl)-1,5-dihydro-1,4,5,6,7,8-hexaazaacenaphthylene as analogues of triciribine.
    Migawa MT; Drach JC; Townsend LB
    J Med Chem; 2005 Jun; 48(11):3840-51. PubMed ID: 15916436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215).
    Cai ZW; Zhang Y; Borzilleri RM; Qian L; Barbosa S; Wei D; Zheng X; Wu L; Fan J; Shi Z; Wautlet BS; Mortillo S; Jeyaseelan R; Kukral DW; Kamath A; Marathe P; D'Arienzo C; Derbin G; Barrish JC; Robl JA; Hunt JT; Lombardo LJ; Fargnoli J; Bhide RS
    J Med Chem; 2008 Mar; 51(6):1976-80. PubMed ID: 18288793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of 3,5-disubstituted-1H-pyrrolo[2,3-b]pyridines as potent inhibitors of the insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase.
    Patnaik S; Stevens KL; Gerding R; Deanda F; Shotwell JB; Tang J; Hamajima T; Nakamura H; Leesnitzer MA; Hassell AM; Shewchuck LM; Kumar R; Lei H; Chamberlain SD
    Bioorg Med Chem Lett; 2009 Jun; 19(11):3136-40. PubMed ID: 19394223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolism of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737): identification of an unusual N-acetylglucosamine conjugate in the cynomolgus monkey.
    Johnson BM; Kamath AV; Leet JE; Liu X; Bhide RS; Tejwani RW; Zhang Y; Qian L; Wei DD; Lombardo LJ; Shu YZ
    Drug Metab Dispos; 2008 Dec; 36(12):2475-83. PubMed ID: 18787055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Research on antineoplastic substances. LI. Derivatives of benzo(f)-pyrrolo-(1,2-a)-quinoxaline and naphtho-(2,1-e)-pyrrolo-(2,1-c)-as-triazine: synthesis and cytostatic and cytotoxic activity].
    Chimenti F; Giuliano R; Vomero S; Artico M; Dolfini E; Morasca L
    Farmaco Sci; 1973; 28(4):284-97. PubMed ID: 4698886
    [No Abstract]   [Full Text] [Related]  

  • 18. Mechanistic studies on a P450-mediated rearrangement of BMS-690514: conversion of a pyrrolotriazine to a hydroxypyridotriazine.
    Hong H; Caceres-Cortes J; Su H; Huang X; Roongta V; Bonacorsi S; Hong Y; Tian Y; Iyer RA; Humphreys WG; Christopher LJ
    Chem Res Toxicol; 2011 Jan; 24(1):125-34. PubMed ID: 21080678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor.
    Bhide RS; Cai ZW; Zhang YZ; Qian L; Wei D; Barbosa S; Lombardo LJ; Borzilleri RM; Zheng X; Wu LI; Barrish JC; Kim SH; Leavitt K; Mathur A; Leith L; Chao S; Wautlet B; Mortillo S; Jeyaseelan R; Kukral D; Hunt JT; Kamath A; Fura A; Vyas V; Marathe P; D'Arienzo C; Derbin G; Fargnoli J
    J Med Chem; 2006 Apr; 49(7):2143-6. PubMed ID: 16570908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The discovery and initial optimisation of pyrrole-2-carboxamides as inhibitors of p38alpha MAP kinase.
    Down K; Bamborough P; Alder C; Campbell A; Christopher JA; Gerelle M; Ludbrook S; Mallett D; Mellor G; Miller DD; Pearson R; Ray K; Solanke Y; Somers D
    Bioorg Med Chem Lett; 2010 Jul; 20(13):3936-40. PubMed ID: 20570148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.